
Opinion|Videos|December 21, 2023
Current and Emerging Standard of Care in NDMM
Author(s)Peter Voorhees, MD
Expert insights into the evolving therapeutic landscape for newly diagnosed multiple myeloma, highlighting transplant eligibility, combination regimens, and emerging data.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































